Arcus Biosciences Inc

RCUS

Company Profile

  • Business description

    Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

  • Contact

    3928 Point Eden Way
    HaywardCA94545
    USA

    T: +1 510 694-6200

    E: [email protected]

    https://www.arcusbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    674

Stocks News & Analysis

stocks

Cheapest ASX member of our Best Idea’s list

This share is trading at the lowest price to fair value of the 14 companies on the list.
stocks

We remove our Moat Rating from ASX listed share

Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks

Best sustainable companies to own in 2026

We believe these companies’ strong ESG management practices give them a long-term advantage.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,996.9037.80-0.42%
CAC 408,176.7834.72-0.42%
DAX 4024,881.2212.530.05%
Dow JONES (US)48,977.18594.791.23%
FTSE 10010,053.3448.770.49%
HKSE26,710.45363.211.38%
NASDAQ23,395.82160.190.69%
Nikkei 22552,518.08685.281.32%
NZX 50 Index13,663.5876.350.56%
S&P 5006,902.0543.580.64%
S&P/ASX 2008,682.8045.80-0.52%
SSE Composite Index4,083.6760.251.50%

Market Movers